Aeon Therapeutics (Shanghai) Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2002)

Organization Overview

First Clinical Trial
2017
NCT03415399
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aeon Therapeutics (Shanghai) Co., Ltd. | Eureka(Beijing) Biotechnology Co., Ltd. | Eureka Therapeutics | Eureka Therapeutics Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Liver Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 8